Pub Date : 2025-09-01Epub Date: 2025-08-26DOI: 10.3904/kjim.2024.360
Hye Jin Bang, Jae-Hyeong Park, Sun Geu Chae, Suk Joo Bae, Ji-Hoon Jung, You Hee Cho, Jong Won Park, Dae-Won Kim, Jung Sun Cho
Background/aims: Transesophageal echocardiography (TEE) is a commonly used imaging modality for assessing embolic stroke of undetermined source (ESUS) in clinical practice. We aimed to develop an automatic plaque segmentation model based on U-net and evaluate its clinical usefulness in patients with ESUS.
Methods: We used two aorta image sets. TEE aortic images of 711 patients visiting two cardiovascular centers for various causes were randomly divided into training, validation, and test sets to automatically segment plaques and estimate the aortic plaque area (APA) and aortic plaque ratio (APR) using U-net. The model was tested in a clinical data set of patients with ESUS who attended three cardiovascular centers to determine whether it could predict a composite cardiovascular event in those patients.
Results: The mean intersection of over union to assess the accuracy of the U-net model was 0.997 ± 0.002 and 0.997 ± 0.001 for the model development and clinical application data sets, respectively. When using the U-net-based model, the APA and APR significantly differed between complex and simple aortic plaques (p < 0.001). However, unlike complex aortic plaques measured in clinical practice, APA or APR estimated by U-net models or manual segmentation did not show additional value in predicting major adverse cardiovascular and cerebrovascular events.
Conclusion: The estimation of APA and APR by the U-net model could be helpful in predicting complex aortic plaques. Additional comprehensive quantitative image analysis of plaque characteristics using artificial intelligence, such as movability and morphology, may be needed to predict prognosis.
{"title":"Automatic quantitative analysis of atherosclerotic aortic plaques in patients with embolic cerebral infarction using deep learning.","authors":"Hye Jin Bang, Jae-Hyeong Park, Sun Geu Chae, Suk Joo Bae, Ji-Hoon Jung, You Hee Cho, Jong Won Park, Dae-Won Kim, Jung Sun Cho","doi":"10.3904/kjim.2024.360","DOIUrl":"10.3904/kjim.2024.360","url":null,"abstract":"<p><strong>Background/aims: </strong>Transesophageal echocardiography (TEE) is a commonly used imaging modality for assessing embolic stroke of undetermined source (ESUS) in clinical practice. We aimed to develop an automatic plaque segmentation model based on U-net and evaluate its clinical usefulness in patients with ESUS.</p><p><strong>Methods: </strong>We used two aorta image sets. TEE aortic images of 711 patients visiting two cardiovascular centers for various causes were randomly divided into training, validation, and test sets to automatically segment plaques and estimate the aortic plaque area (APA) and aortic plaque ratio (APR) using U-net. The model was tested in a clinical data set of patients with ESUS who attended three cardiovascular centers to determine whether it could predict a composite cardiovascular event in those patients.</p><p><strong>Results: </strong>The mean intersection of over union to assess the accuracy of the U-net model was 0.997 ± 0.002 and 0.997 ± 0.001 for the model development and clinical application data sets, respectively. When using the U-net-based model, the APA and APR significantly differed between complex and simple aortic plaques (p < 0.001). However, unlike complex aortic plaques measured in clinical practice, APA or APR estimated by U-net models or manual segmentation did not show additional value in predicting major adverse cardiovascular and cerebrovascular events.</p><p><strong>Conclusion: </strong>The estimation of APA and APR by the U-net model could be helpful in predicting complex aortic plaques. Additional comprehensive quantitative image analysis of plaque characteristics using artificial intelligence, such as movability and morphology, may be needed to predict prognosis.</p>","PeriodicalId":48785,"journal":{"name":"Korean Journal of Internal Medicine","volume":" ","pages":"767-779"},"PeriodicalIF":2.4,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12425677/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144975299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-01Epub Date: 2025-03-25DOI: 10.3904/kjim.2024.399
Oh-Hyun Lee, Ji Woong Roh, Yongcheol Kim, Eui Im, Deok-Kyu Cho
Background/aims: Data on the interactions between clopidogrel and tegoprazan are limited. We compared the effects of tegoprazan and proton-pump inhibitors (PPIs) on platelet reactivity.
Methods: Using database data from March 2020 to January 2023, we retrospectively evaluated 262 patients who were taking either tegoprazan (n = 107) or PPIs (n = 155) combined with dual antiplatelet therapy, including aspirin and clopidogrel, after percutaneous coronary intervention. Platelet reactivity was assessed using VerifyNow P2Y12 assays.
Results: Platelet reaction unit (PRU) values at 3 (157 ± 8 vs. 162 ± 6, p = 0.659), 6 (167 ± 9 vs. 158 ± 7, p = 0.370), and 12 months (155 ± 10 vs. 164 ± 7, p = 0.448) were similar between groups. The prevalence of high on-treatment platelet reactivity, defined as ≥ 253 PRU, was also similar between the groups at 3 (10.3% vs. 10.2%, p = 0.976), 6 (7.0% vs. 8.2%, p = 1.000), and 12 months (4.3% vs. 9.0%, p = 0.503).
Conclusion: There was no significant difference in platelet reactivity between the tegoprazan and PPI groups in patients undergoing PCI and receiving dual antiplatelet therapy with clopidogrel.
背景/目的:有关氯吡格雷和替戈普拉赞之间相互作用的数据有限。我们比较了替戈拉赞和质子泵抑制剂(PPI)对血小板反应性的影响:利用 2020 年 3 月至 2023 年 1 月的数据库数据,我们对 262 例经皮冠状动脉介入治疗后服用替戈普赞(107 例)或质子泵抑制剂(155 例)并联合阿司匹林和氯吡格雷等双联抗血小板疗法的患者进行了回顾性评估。使用VerifyNow P2Y12测定法评估血小板反应性:3个月(157 ± 8 vs. 162 ± 6,p = 0.659)、6个月(167 ± 9 vs. 158 ± 7,p = 0.370)和12个月(155 ± 10 vs. 164 ± 7,p = 0.448)时的血小板反应单位(PRU)值在组间相似。在治疗 3 个月(10.3% vs. 10.2%,p = 0.976)、6 个月(7.0% vs. 8.2%,p = 1.000)和 12 个月(4.3% vs. 9.0%,p = 0.503)时,治疗组之间血小板高反应性(定义为 PRU ≥ 253)的发生率也相似:在接受PCI并使用氯吡格雷进行双重抗血小板治疗的患者中,替戈普拉赞组和PPI组的血小板反应性没有明显差异。
{"title":"Effect of tegoprazan on temporal variability of platelet reactivity in patients treated with clopidogrel after coronary stenting.","authors":"Oh-Hyun Lee, Ji Woong Roh, Yongcheol Kim, Eui Im, Deok-Kyu Cho","doi":"10.3904/kjim.2024.399","DOIUrl":"10.3904/kjim.2024.399","url":null,"abstract":"<p><strong>Background/aims: </strong>Data on the interactions between clopidogrel and tegoprazan are limited. We compared the effects of tegoprazan and proton-pump inhibitors (PPIs) on platelet reactivity.</p><p><strong>Methods: </strong>Using database data from March 2020 to January 2023, we retrospectively evaluated 262 patients who were taking either tegoprazan (n = 107) or PPIs (n = 155) combined with dual antiplatelet therapy, including aspirin and clopidogrel, after percutaneous coronary intervention. Platelet reactivity was assessed using VerifyNow P2Y12 assays.</p><p><strong>Results: </strong>Platelet reaction unit (PRU) values at 3 (157 ± 8 vs. 162 ± 6, p = 0.659), 6 (167 ± 9 vs. 158 ± 7, p = 0.370), and 12 months (155 ± 10 vs. 164 ± 7, p = 0.448) were similar between groups. The prevalence of high on-treatment platelet reactivity, defined as ≥ 253 PRU, was also similar between the groups at 3 (10.3% vs. 10.2%, p = 0.976), 6 (7.0% vs. 8.2%, p = 1.000), and 12 months (4.3% vs. 9.0%, p = 0.503).</p><p><strong>Conclusion: </strong>There was no significant difference in platelet reactivity between the tegoprazan and PPI groups in patients undergoing PCI and receiving dual antiplatelet therapy with clopidogrel.</p>","PeriodicalId":48785,"journal":{"name":"Korean Journal of Internal Medicine","volume":" ","pages":"759-766"},"PeriodicalIF":2.4,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12425681/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143701829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-01Epub Date: 2025-08-26DOI: 10.3904/kjim.2024.314
Ji-Yong Moon, Joon Young Choi, Youlim Kim, Hye Jung Park, Yong Bum Park, Seong Yong Lim, Kyung Hoon Min, Deog Kyeom Kim, Chin Kook Rhee, Seung Won Ra, Chang Youl Lee, Yong Il Hwang, Kwang Ha Yoo
Background/aims: This study evaluated the non-inferiority of HL-301 to erdosteine in terms of symptom relief and the anti- inflammatory effects in acute bronchitis patients not treated with antibiotics.
Methods: In a double-blind, non-inferiority trial, patients were randomized 1:1 to receive either HL-301 (300 mg twice daily) or erdosteine (300 mg three times daily) for seven days. The primary endpoint was change in total Bronchitis Severity Score (BSS) from baseline to day 7. The non-inferiority margin was set at -0.99 for the difference in BSS change. The secondary endpoints were changes in specific symptoms, overall improvement, patient satisfaction, and inflammatory markers.
Results: Mean BSS reduction at day 7 was -4.43 in the HL-301 group (n = 53) and -4.33 in the erdosteine group (n = 52). The difference in mean BSS change between the groups was 0.11, with the lower limit of the 97.5% one-sided confidence interval at -0.42, confirming non-inferiority. The improvement in specific symptoms, overall improvement, and patient satisfaction were high in both groups; however, there were no significant differences between the groups. Additionally, the changes in C-reactive protein, tumor necrosis factor-alpha, interleukin (IL)-1β, and IL-6 were similar between the groups, with no significant differences observed. The incidence of adverse events was higher in the HL-301 group compared to the erdosteine group, including gastrointestinal disorder, periodontitis, and increased blood cholesterol, although this difference was not statistically significant.
Conclusion: HL-301 was non-inferior to erdosteine, confirming its positive effect on symptom relief in acute bronchitis patients managed with conservative care.
{"title":"Efficacy and safety of HL-301 compared with erdosteine in acute bronchitis: a randomized, double-blind, non-inferiority trial.","authors":"Ji-Yong Moon, Joon Young Choi, Youlim Kim, Hye Jung Park, Yong Bum Park, Seong Yong Lim, Kyung Hoon Min, Deog Kyeom Kim, Chin Kook Rhee, Seung Won Ra, Chang Youl Lee, Yong Il Hwang, Kwang Ha Yoo","doi":"10.3904/kjim.2024.314","DOIUrl":"10.3904/kjim.2024.314","url":null,"abstract":"<p><strong>Background/aims: </strong>This study evaluated the non-inferiority of HL-301 to erdosteine in terms of symptom relief and the anti- inflammatory effects in acute bronchitis patients not treated with antibiotics.</p><p><strong>Methods: </strong>In a double-blind, non-inferiority trial, patients were randomized 1:1 to receive either HL-301 (300 mg twice daily) or erdosteine (300 mg three times daily) for seven days. The primary endpoint was change in total Bronchitis Severity Score (BSS) from baseline to day 7. The non-inferiority margin was set at -0.99 for the difference in BSS change. The secondary endpoints were changes in specific symptoms, overall improvement, patient satisfaction, and inflammatory markers.</p><p><strong>Results: </strong>Mean BSS reduction at day 7 was -4.43 in the HL-301 group (n = 53) and -4.33 in the erdosteine group (n = 52). The difference in mean BSS change between the groups was 0.11, with the lower limit of the 97.5% one-sided confidence interval at -0.42, confirming non-inferiority. The improvement in specific symptoms, overall improvement, and patient satisfaction were high in both groups; however, there were no significant differences between the groups. Additionally, the changes in C-reactive protein, tumor necrosis factor-alpha, interleukin (IL)-1β, and IL-6 were similar between the groups, with no significant differences observed. The incidence of adverse events was higher in the HL-301 group compared to the erdosteine group, including gastrointestinal disorder, periodontitis, and increased blood cholesterol, although this difference was not statistically significant.</p><p><strong>Conclusion: </strong>HL-301 was non-inferior to erdosteine, confirming its positive effect on symptom relief in acute bronchitis patients managed with conservative care.</p>","PeriodicalId":48785,"journal":{"name":"Korean Journal of Internal Medicine","volume":" ","pages":"790-800"},"PeriodicalIF":2.4,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12425675/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144975294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-01Epub Date: 2025-08-29DOI: 10.3904/kjim.2025.251
Jong Shin Woo
{"title":"Turning evidence into action: the real challenge of guideline-directed medical therapy in acute myocardial infarction.","authors":"Jong Shin Woo","doi":"10.3904/kjim.2025.251","DOIUrl":"10.3904/kjim.2025.251","url":null,"abstract":"","PeriodicalId":48785,"journal":{"name":"Korean Journal of Internal Medicine","volume":"40 5","pages":"693-695"},"PeriodicalIF":2.4,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12425683/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145016441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-01Epub Date: 2025-08-26DOI: 10.3904/kjim.2025.037
Nam Su Ku, Yongseop Lee, Dae Won Park
Evidence supporting antibiotic administration within 3 hours in sepsis without shock is limited. Therefore, we conducted a systematic review and meta-analysis to determine whether the timing of antibiotic initiation influences mortality in patients with sepsis or septic shock. We comprehensively searched PubMed, EMBASE, the Cochrane Central Register of Controlled Trials, and the Korean Medical Database from inception to November, 2022, using the keywords "sepsis," "septic shock," "anti-bacterial agents," "time to treatment," and "time factors." Two reviewers independently performed eligibility screening and full-text review. Thirteen studies including 79,246 patients were analyzed: five prospective, seven retrospective, and one retrospective case-control study. In overall sepsis cases, mortality did not differ significantly between patients who received antibiotics within 1 hour and those in the delayed group but was significantly lower in those who received antibiotics within 3 hours than in those in the delayed group. In patients with septic shock, mortality was significantly lower in groups that received antibiotics within both 1 and 3 hours than in the delayed group. In septic shock, administration of antibiotics within 1 hour of diagnosis reduces mortality. In patients with sepsis, antibiotic administration within 3 hours, but not necessarily within 1 hour, was associated with reduced mortality.
{"title":"Appropriate timing of antibiotic initiation in patients with sepsis or septic shock: a systematic review and meta-analysis.","authors":"Nam Su Ku, Yongseop Lee, Dae Won Park","doi":"10.3904/kjim.2025.037","DOIUrl":"10.3904/kjim.2025.037","url":null,"abstract":"<p><p>Evidence supporting antibiotic administration within 3 hours in sepsis without shock is limited. Therefore, we conducted a systematic review and meta-analysis to determine whether the timing of antibiotic initiation influences mortality in patients with sepsis or septic shock. We comprehensively searched PubMed, EMBASE, the Cochrane Central Register of Controlled Trials, and the Korean Medical Database from inception to November, 2022, using the keywords \"sepsis,\" \"septic shock,\" \"anti-bacterial agents,\" \"time to treatment,\" and \"time factors.\" Two reviewers independently performed eligibility screening and full-text review. Thirteen studies including 79,246 patients were analyzed: five prospective, seven retrospective, and one retrospective case-control study. In overall sepsis cases, mortality did not differ significantly between patients who received antibiotics within 1 hour and those in the delayed group but was significantly lower in those who received antibiotics within 3 hours than in those in the delayed group. In patients with septic shock, mortality was significantly lower in groups that received antibiotics within both 1 and 3 hours than in the delayed group. In septic shock, administration of antibiotics within 1 hour of diagnosis reduces mortality. In patients with sepsis, antibiotic administration within 3 hours, but not necessarily within 1 hour, was associated with reduced mortality.</p>","PeriodicalId":48785,"journal":{"name":"Korean Journal of Internal Medicine","volume":" ","pages":"725-733"},"PeriodicalIF":2.4,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12425674/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144975249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-01Epub Date: 2025-08-26DOI: 10.3904/kjim.2025.107
SeungYong Park, Seoung Ju Park
Lung cancer remains a leading cause of cancer-related mortality worldwide and is often diagnosed at an advanced stage, with poor survival outcomes. Early detection and appropriate management of incidental pulmonary nodules, frequently identified through low-dose computed tomography screening, are critical for improving prognosis and reducing lung cancer mortality. Established guidelines, including those of the Fleischner Society and American College of Radiology, provide structured recommendations for risk assessment, surveillance, and intervention. Recent advancements in diagnostic modalities, such as positron emission tomography, endobronchial ultrasound, electromagnetic navigation bronchoscopy, and robot-assisted bronchoscopy, have enhanced the diagnostic accuracy while minimizing procedural risks. A multidisciplinary approach that incorporates these technologies is essential for optimizing patient care. This review summarizes the current strategies for evaluating and managing solitary pulmonary nodules, including risk stratification models, imaging features, and biopsy techniques, thereby providing a comprehensive overview for clinicians.
{"title":"Diagnostic approach for incidental pulmonary nodules.","authors":"SeungYong Park, Seoung Ju Park","doi":"10.3904/kjim.2025.107","DOIUrl":"10.3904/kjim.2025.107","url":null,"abstract":"<p><p>Lung cancer remains a leading cause of cancer-related mortality worldwide and is often diagnosed at an advanced stage, with poor survival outcomes. Early detection and appropriate management of incidental pulmonary nodules, frequently identified through low-dose computed tomography screening, are critical for improving prognosis and reducing lung cancer mortality. Established guidelines, including those of the Fleischner Society and American College of Radiology, provide structured recommendations for risk assessment, surveillance, and intervention. Recent advancements in diagnostic modalities, such as positron emission tomography, endobronchial ultrasound, electromagnetic navigation bronchoscopy, and robot-assisted bronchoscopy, have enhanced the diagnostic accuracy while minimizing procedural risks. A multidisciplinary approach that incorporates these technologies is essential for optimizing patient care. This review summarizes the current strategies for evaluating and managing solitary pulmonary nodules, including risk stratification models, imaging features, and biopsy techniques, thereby providing a comprehensive overview for clinicians.</p>","PeriodicalId":48785,"journal":{"name":"Korean Journal of Internal Medicine","volume":" ","pages":"710-724"},"PeriodicalIF":2.4,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12425691/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144975321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-01Epub Date: 2025-08-29DOI: 10.3904/kjim.2025.171
Junyeol Kim, Kyeongmin Lee, Jiyeon Oh, Hayeon Lee, Jong-In Chang, Tae Young Park, Dong Keon Yon, Hyoung-Chul Oh
Background/aims: Herpes zoster (HZ) vaccination is primarily administered to prevent shingles, yet its systemic immunomodulatory effects may offer protection against other organ-related diseases, including hepatobiliary and pancreatic diseases. Therefore, this emulated target trial aimed to evaluate whether live HZ vaccination reduces the long-term risk of hepatobiliary diseases in older adults.
Methods: We conducted a nationwide, population-based cohort study in South Korea (n = 2,207,784 individuals aged ≥ 50 years) from January 1, 2012, to December 31, 2021, with follow-up until January 31, 2024. This cohort was built by merging health insurance (Korea Health Insurance Review and Assessment Service), national health screening (Korean National Health Insurance Service), and vaccination records (Korea Disease Control and Prevention Agency). To assess the risk of any hepatobiliary diseases and eight subcategories following HZ vaccination, we performed 1:1 exposure-driven propensity score matching and estimated adjusted hazard ratios (aHRs) using Cox proportional hazards models.
Results: After matching, 1,462,070 individuals were included (mean age, 61.57 years; 56.26% females). HZ vaccination was associated with a 14% lower risk of developing any hepatobiliary events (aHR 0.86, 95% CI 0.85-0.87). Risk reductions were consistent across all subcategories, notably for hepatic failure (aHR 0.71, 95% CI 0.63-0.78) and liver cirrhosis (aHR 0.74, 95% CI 0.70-0.77). Protective associations were more pronounced in males, younger individuals (< 60 years), and smokers. The benefit persisted for eight years, peaking within the first four years.
Conclusion: HZ vaccination was associated with significantly reducing hepatobiliary and pancreatic diseases, supporting potential broader health benefits beyond shingles prevention in older adults.
背景/目的:带状疱疹(HZ)疫苗接种主要用于预防带状疱疹,但其全身免疫调节作用可能提供对其他器官相关疾病的保护,包括肝胆和胰腺疾病。因此,本模拟目标试验旨在评估活HZ疫苗接种是否降低老年人肝胆疾病的长期风险。方法:2012年1月1日至2021年12月31日,我们在韩国开展了一项全国性的、基于人群的队列研究(n = 2207,784例年龄≥50岁的个体),随访至2024年1月31日。该队列是通过合并健康保险(韩国健康保险审查评估院)、国民健康检查(韩国国民健康保险院)和疫苗接种记录(韩国疾病管理本部)而建立的。为了评估HZ疫苗接种后任何肝胆疾病和8个亚类别的风险,我们进行了1:1的暴露驱动倾向评分匹配,并使用Cox比例风险模型估计调整风险比(aHRs)。结果:匹配后共纳入1462070人,平均年龄61.57岁,女性占56.26%。HZ疫苗接种与发生任何肝胆事件的风险降低14%相关(aHR 0.86, 95% CI 0.85-0.87)。所有亚类别的风险降低是一致的,特别是肝功能衰竭(aHR 0.71, 95% CI 0.63-0.78)和肝硬化(aHR 0.74, 95% CI 0.70-0.77)。保护性关联在男性、年轻人(< 60岁)和吸烟者中更为明显。这种益处持续了8年,并在头4年达到顶峰。结论:HZ疫苗接种与显著减少肝胆和胰腺疾病相关,支持潜在的更广泛的健康益处,而不仅仅是预防老年人带状疱疹。
{"title":"Live zoster vaccination and hepatobiliary risk reduction: a nationwide South Korean study.","authors":"Junyeol Kim, Kyeongmin Lee, Jiyeon Oh, Hayeon Lee, Jong-In Chang, Tae Young Park, Dong Keon Yon, Hyoung-Chul Oh","doi":"10.3904/kjim.2025.171","DOIUrl":"10.3904/kjim.2025.171","url":null,"abstract":"<p><strong>Background/aims: </strong>Herpes zoster (HZ) vaccination is primarily administered to prevent shingles, yet its systemic immunomodulatory effects may offer protection against other organ-related diseases, including hepatobiliary and pancreatic diseases. Therefore, this emulated target trial aimed to evaluate whether live HZ vaccination reduces the long-term risk of hepatobiliary diseases in older adults.</p><p><strong>Methods: </strong>We conducted a nationwide, population-based cohort study in South Korea (n = 2,207,784 individuals aged ≥ 50 years) from January 1, 2012, to December 31, 2021, with follow-up until January 31, 2024. This cohort was built by merging health insurance (Korea Health Insurance Review and Assessment Service), national health screening (Korean National Health Insurance Service), and vaccination records (Korea Disease Control and Prevention Agency). To assess the risk of any hepatobiliary diseases and eight subcategories following HZ vaccination, we performed 1:1 exposure-driven propensity score matching and estimated adjusted hazard ratios (aHRs) using Cox proportional hazards models.</p><p><strong>Results: </strong>After matching, 1,462,070 individuals were included (mean age, 61.57 years; 56.26% females). HZ vaccination was associated with a 14% lower risk of developing any hepatobiliary events (aHR 0.86, 95% CI 0.85-0.87). Risk reductions were consistent across all subcategories, notably for hepatic failure (aHR 0.71, 95% CI 0.63-0.78) and liver cirrhosis (aHR 0.74, 95% CI 0.70-0.77). Protective associations were more pronounced in males, younger individuals (< 60 years), and smokers. The benefit persisted for eight years, peaking within the first four years.</p><p><strong>Conclusion: </strong>HZ vaccination was associated with significantly reducing hepatobiliary and pancreatic diseases, supporting potential broader health benefits beyond shingles prevention in older adults.</p>","PeriodicalId":48785,"journal":{"name":"Korean Journal of Internal Medicine","volume":"40 5","pages":"747-758"},"PeriodicalIF":2.4,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12425680/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145016480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-01Epub Date: 2025-07-17DOI: 10.3904/kjim.2025.004
Hwa-Young Lee, Sung Gyul Lim, Han Sang Lee, Won-Ae Lee, So Mi Kim
{"title":"Findings suggestive of Fanconi syndrome and multiple myeloma.","authors":"Hwa-Young Lee, Sung Gyul Lim, Han Sang Lee, Won-Ae Lee, So Mi Kim","doi":"10.3904/kjim.2025.004","DOIUrl":"10.3904/kjim.2025.004","url":null,"abstract":"","PeriodicalId":48785,"journal":{"name":"Korean Journal of Internal Medicine","volume":" ","pages":"856-857"},"PeriodicalIF":2.4,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12425687/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144643925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-01Epub Date: 2025-08-26DOI: 10.3904/kjim.2025.006
Jeongmin Lee, Jeongeun Kwak, Min-Hee Kim, Seung-Hwan Lee, Jae-Hyoung Cho, Dong-Jun Lim, Jung Min Lee, Sang-Ah Chang, Hun-Sung Kim
Background/aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) is associated with various metabolic disorders; however, its relationship with thyroid cancer remains unclear. This study investigated the association between MASLD and the risk of thyroid cancer.
Methods: This retrospective cohort study used data from the Korean National Health Insurance Service database on individuals who underwent three or more health examinations between January 2002 and December 2015. MASLD was diagnosed using the Hepatic Steatosis Index. Participants were followed up until December 31, 2019, to assess the incidence of newly diagnosed thyroid cancer.
Results: A total of 121,479 individuals were included in this study. In the age- and sex-adjusted analysis, the risk of thyroid cancer was significantly higher in the MASLD group than in the normal group (HR 1.19, 95% CI 1.11-1.29, p < 0.001). Age was a significant effect modifier of the relationship between MASLD and thyroid cancer (p for interaction < 0.05). Among individuals aged 65 years or older, the risk of thyroid cancer was higher in the MASLD group than in the normal group (HR 1.31, 95% CI 1.00-1.72, p = 0.05), whereas in individuals younger than 65 years, MASLD was not associated with thyroid cancer (HR 0.97, 95% CI 0.89-1.04, p = 0.37).
Conclusion: This study suggests an association between MASLD and an increased risk of thyroid cancer in older adults. However, further research is needed to determine whether lifestyle modifications, such as weight management, influence thyroid cancer risk in this population.
背景/目的:代谢功能障碍相关脂肪变性肝病(MASLD)与多种代谢紊乱相关;然而,它与甲状腺癌的关系尚不清楚。本研究调查了MASLD与甲状腺癌风险之间的关系。方法:本回顾性队列研究使用了2002年1月至2015年12月期间接受过三次或以上健康检查的韩国国民健康保险服务数据库中的数据。使用肝脂肪变性指数诊断MASLD。参与者被随访至2019年12月31日,以评估新诊断的甲状腺癌的发病率。结果:本研究共纳入121479名个体。在年龄和性别调整分析中,MASLD组患甲状腺癌的风险显著高于正常组(HR 1.19, 95% CI 1.11-1.29, p < 0.001)。年龄是MASLD与甲状腺癌关系的显著影响因子(交互作用p < 0.05)。在65岁及以上的个体中,MASLD组患甲状腺癌的风险高于正常组(HR 1.31, 95% CI 1.00-1.72, p = 0.05),而在65岁以下的个体中,MASLD与甲状腺癌无关(HR 0.97, 95% CI 0.89-1.04, p = 0.37)。结论:本研究提示MASLD与老年人甲状腺癌风险增加之间存在关联。然而,需要进一步的研究来确定生活方式的改变,如体重管理,是否会影响这一人群患甲状腺癌的风险。
{"title":"Association between metabolic dysfunction-associated steatotic liver disease and the risk of thyroid cancer: a nationwide cohort study.","authors":"Jeongmin Lee, Jeongeun Kwak, Min-Hee Kim, Seung-Hwan Lee, Jae-Hyoung Cho, Dong-Jun Lim, Jung Min Lee, Sang-Ah Chang, Hun-Sung Kim","doi":"10.3904/kjim.2025.006","DOIUrl":"10.3904/kjim.2025.006","url":null,"abstract":"<p><strong>Background/aims: </strong>Metabolic dysfunction-associated steatotic liver disease (MASLD) is associated with various metabolic disorders; however, its relationship with thyroid cancer remains unclear. This study investigated the association between MASLD and the risk of thyroid cancer.</p><p><strong>Methods: </strong>This retrospective cohort study used data from the Korean National Health Insurance Service database on individuals who underwent three or more health examinations between January 2002 and December 2015. MASLD was diagnosed using the Hepatic Steatosis Index. Participants were followed up until December 31, 2019, to assess the incidence of newly diagnosed thyroid cancer.</p><p><strong>Results: </strong>A total of 121,479 individuals were included in this study. In the age- and sex-adjusted analysis, the risk of thyroid cancer was significantly higher in the MASLD group than in the normal group (HR 1.19, 95% CI 1.11-1.29, p < 0.001). Age was a significant effect modifier of the relationship between MASLD and thyroid cancer (p for interaction < 0.05). Among individuals aged 65 years or older, the risk of thyroid cancer was higher in the MASLD group than in the normal group (HR 1.31, 95% CI 1.00-1.72, p = 0.05), whereas in individuals younger than 65 years, MASLD was not associated with thyroid cancer (HR 0.97, 95% CI 0.89-1.04, p = 0.37).</p><p><strong>Conclusion: </strong>This study suggests an association between MASLD and an increased risk of thyroid cancer in older adults. However, further research is needed to determine whether lifestyle modifications, such as weight management, influence thyroid cancer risk in this population.</p>","PeriodicalId":48785,"journal":{"name":"Korean Journal of Internal Medicine","volume":" ","pages":"813-822"},"PeriodicalIF":2.4,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12425684/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144975257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jung-Bin Park, Ji Eun Baek, June Hwa Bae, Seung Wook Hong, Sung Wook Hwang, Sang Hyoung Park, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Dong-Hoon Yang
Background/aims: This study aimed to evaluate the feasibility and outcomes of mini-probe endoscopic ultrasound (mEUS) followed by submucosal saline injection (SSI-mEUS) for assessing the endoscopic resectability of colorectal subepithelial lesions (SELs).
Methods: From January 2020 to December 2023, the medical records of 391 SELs (364 patients) were retrospectively reviewed and categorized into no EUS, mEUS-only, and SSI-mEUS groups according to the procedure used. To compare variables between the SSI-mEUS and other groups, the no EUS and mEUS-only groups were combined into the non-SSI-mEUS group. In the SSI-mEUS group, submucosal cushion thickness was endosonographically measured after the saline injection. Treatment outcomes and histological diagnosis were retrospectively reviewed.
Results: A total of 210 lesions in the no EUS group, 23 in the mEUS-only group, and 125 in the SSI-mEUS group were endoscopically resected. The mean SEL size was larger in the SSI-mEUS than in the non-SSI-mEUS group (6.8 ± 2.6 mm vs. 4.9 ± 2.6 mm, p < 0.001). R0 resection was achieved in 107 of 110 neoplastic lesions (97.3%) in the SSI-mEUS group vs. 159 of 176 neoplastic lesions (90.3%) in the non-SSI-mEUS group (p = 0.046). Not using SSI-mEUS was the only factor associated with indeterminate or positive deep resection margins (odds ratio 3.45, 95% confidence interval 1.19-13.40, p = 0.021).
Conclusion: For colorectal SELs, including those that appear insufficiently elevated during conventional endoscopy, SSI-mEUS enables an objective assessment of the feasibility of endoscopic resection and can predict a high likelihood of achieving a safe and complete resection.
背景/目的:本研究旨在评估微型探针内镜超声(mEUS)联合粘膜下生理盐水注射(SSI-mEUS)评估结肠直肠上皮下病变(SELs)内镜可切除性的可行性和结果。方法:回顾性分析2020年1月至2023年12月391例SELs患者(364例)的医疗记录,并根据使用的方法将其分为无EUS、仅meus和SSI-mEUS组。为了比较SSI-mEUS与其他组之间的变量,将无EUS组和仅meus组合并为无SSI-mEUS组。SSI-mEUS组在生理盐水注射后通过超声测量粘膜下垫层厚度。回顾性分析治疗结果和组织学诊断。结果:无EUS组共切除病变210例,仅meus组23例,SSI-mEUS组125例。SSI-mEUS组的平均SEL大小大于非SSI-mEUS组(6.8±2.6 mm vs. 4.9±2.6 mm, p < 0.001)。SSI-mEUS组110个肿瘤病灶中有107个(97.3%)实现R0切除术,而非SSI-mEUS组176个肿瘤病灶中有159个(90.3%)实现R0切除术(p = 0.046)。未使用si - meus是导致深切边缘不确定或阳性的唯一因素(优势比3.45,95%可信区间1.19-13.40,p = 0.021)。结论:对于结直肠SELs,包括那些在常规内镜检查中出现升高不足的SELs, SSI-mEUS能够客观评估内镜切除的可行性,并可以预测实现安全和完全切除的高可能性。
{"title":"Submucosal saline injection and mini-probe endoscopic ultrasound to assess endoscopic resectability of colorectal subepithelial tumors.","authors":"Jung-Bin Park, Ji Eun Baek, June Hwa Bae, Seung Wook Hong, Sung Wook Hwang, Sang Hyoung Park, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Dong-Hoon Yang","doi":"10.3904/kjim.2024.384","DOIUrl":"10.3904/kjim.2024.384","url":null,"abstract":"<p><strong>Background/aims: </strong>This study aimed to evaluate the feasibility and outcomes of mini-probe endoscopic ultrasound (mEUS) followed by submucosal saline injection (SSI-mEUS) for assessing the endoscopic resectability of colorectal subepithelial lesions (SELs).</p><p><strong>Methods: </strong>From January 2020 to December 2023, the medical records of 391 SELs (364 patients) were retrospectively reviewed and categorized into no EUS, mEUS-only, and SSI-mEUS groups according to the procedure used. To compare variables between the SSI-mEUS and other groups, the no EUS and mEUS-only groups were combined into the non-SSI-mEUS group. In the SSI-mEUS group, submucosal cushion thickness was endosonographically measured after the saline injection. Treatment outcomes and histological diagnosis were retrospectively reviewed.</p><p><strong>Results: </strong>A total of 210 lesions in the no EUS group, 23 in the mEUS-only group, and 125 in the SSI-mEUS group were endoscopically resected. The mean SEL size was larger in the SSI-mEUS than in the non-SSI-mEUS group (6.8 ± 2.6 mm vs. 4.9 ± 2.6 mm, p < 0.001). R0 resection was achieved in 107 of 110 neoplastic lesions (97.3%) in the SSI-mEUS group vs. 159 of 176 neoplastic lesions (90.3%) in the non-SSI-mEUS group (p = 0.046). Not using SSI-mEUS was the only factor associated with indeterminate or positive deep resection margins (odds ratio 3.45, 95% confidence interval 1.19-13.40, p = 0.021).</p><p><strong>Conclusion: </strong>For colorectal SELs, including those that appear insufficiently elevated during conventional endoscopy, SSI-mEUS enables an objective assessment of the feasibility of endoscopic resection and can predict a high likelihood of achieving a safe and complete resection.</p>","PeriodicalId":48785,"journal":{"name":"Korean Journal of Internal Medicine","volume":"40 4","pages":"592-605"},"PeriodicalIF":2.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12257020/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144601975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}